Salute e Benessere
MolecuLight Showcases 10 Scientific Posters at SAWC Fall and Announces Upcoming Oxygenation Imaging on the MolecuLightDX®+ Platform
MolecuLight is advancing its technology by expanding the MolecuLight imaging platform to include oxygenation imaging—delivering all vital wound care imaging in one compact, fully handheld system that maximizes clinician time and documentation, with FDA submission expected Q4 2025. This new capability will allow clinicians to assess oxygenation, detect bacterial burden, accurately measure wounds, and see thermal changes from a single device—eliminating the need to rely on multiple technologies.
The device already integrates seamlessly with leading EHRs (such as Epic), and this addition further drives clinical efficiency and expedites clinical workflows. As a fully secure, HIPAA-compliant, SOC 2 certified product backed by extensive clinical evidence including over 100 peer-reviewed publications, MolecuLight can be used with confidence on any wound, across any site of service. In addition, MolecuLight is expecting MDDT (Medical Device Development Tool) FDA qualification this fall for the measurement feature. This designation will further validate the accuracy and reproducibility of MolecuLight's wound measurement technology and qualify it as a reliable tool for assessing clinical trial outcomes for other wound care products and companies.
"SAWC Fall is a leading forum for advancing wound care, and we're proud to contribute 10 scientific posters that showcase the broad clinical value of MolecuLight's technology," said Anil Amlani, CEO of MolecuLight. "From engaging patients in their care, to guiding surgeons intraoperatively, improving debridement, and introducing novel thermal imaging insights, our platform is transforming wound assessment. With the upcoming addition of oxygenation imaging and anticipated FDA clearance of our wound measurement technology as a Medical Device Development Tool, the MolecuLight is set to become the most comprehensive, all-in-one handheld imaging solution for clinicians and researchers alike."
SAWC Fall attendees are invited to visit MolecuLight at Booth #327 for live demonstrations of its imaging technology and to see how the MolecuLight is transforming wound assessment, documentation, and patient outcomes—while integrating seamlessly into everyday clinical workflows.
MolecuLight is a privately owned medical imaging company with a global presence that manufactures and commercializes the MolecuLight
® and wound imaging devices. These class II FDA-cleared point-of-care imaging devices for the real-time detection of elevated bacterial burden in wounds also provide thermal imaging and accurate digital wound measurement for comprehensive wound management, supported by strong clinical evidence including over 100 peer-reviewed publications.
www.moleculight.com
SAWC Fall is the nation's leading multidisciplinary wound care conference, bringing together clinicians, researchers, and industry leaders to shape the future of wound management. Through its diverse program of education, workshops, and scientific presentations, SAWC promotes collaboration and innovation that enhance patient outcomes worldwide.
For sales, media or other inquiries or further information, please contact: Danielle Dunham, Director of Product and Marketing, MolecuLight Inc., T. +1.416.542.5524, ddunham@moleculight.com
Photo - https://mma.prnewswire.com/media/2764191/MolecuLight_MolecuLight_Showcases_10_Scientific_Posters_at_SAWC.jpg
Logo - https://mma.prnewswire.com/media/2764190/MolecuLight_MolecuLight_Showcases_10_Scientific_Posters_at_SAWC.jpg
View original content:https://www.prnewswire.co.uk/news-releases/moleculight-showcases-10-scientific-posters-at-sawc-fall-and-announces-upcoming-oxygenation-imaging-on-the-moleculightdx-platform-302546067.html